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SUMMARY
Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis
genes from a large number of random genetic alterations. Here we use a computational algorithm to map
minimal recurrent genomic alterations associated with poor-prognosis breast cancer. 8q22 genomic gain
was identified by this approach and validated in an extensive collection of breast tumor samples. Regional
gain of 8q22 elevates expression of the metastasis gene metadherin (MTDH), which is overexpressed in
more than 40% of breast cancers and is associated with poor clinical outcomes. Functional characterization
of MTDH revealed its dual role in promotingmetastatic seeding and enhancing chemoresistance. These find-
ings establishMTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy
and reducing metastasis risk.INTRODUCTION
The progression of cancer from an abnormal outgrowth to a
life-threatening metastatic tumor is accompanied by a myriad
of genetic and epigenetic alterations accumulated along the
way (Chin and Gray, 2008; Fidler, 2003; Gupta and Massague´,
2006; Hanahan and Weinberg, 2000; Steeg, 2006). The chal-
lenge of distinguishing crucial drivers of metastasis from thou-
sands of bystander alterations remains a major bottleneck in
metastasis research. The turn of the 21st century has witnessed
the advent of two parallel but individually incomplete genomicapproaches to unravel the genetic mystery of cancer metastasis
(Kang, 2005). Comparative expression profiling analyses of can-
cer cell line variants with different metastasis potentials, often
obtained by in vivo selection in animal models, have led to the
identification of several metastasis genes (Clark et al., 2000;
Kang et al., 2003; Minn et al., 2005; Yang et al., 2004). However,
much work remains to be done to validate the clinical relevance
of metastasis genes identified in animal model studies. A second
approach, gene expression profiling of human tumor specimens,
has enabled the identification of several poor-prognosis signa-
tures that are predictive of recurrence and metastasis risk inSIGNIFICANCE
Genomic profiling of breast cancer has established several clinically applicable poor-prognosis gene signatures. However,
the lack of overlap between independent signatures prevents the identification of functionally important genes in the signa-
tures. Here we report an integrative strategy to identify recurrent genomic alterations that are both clinically relevant and
functionally important for breast cancer progression. Successful application of this approach led to the identification of
metadherin (MTDH) at the recurrent 8q22 poor-prognosis genomic gain with important functions in both metastasis and
chemoresistance. The dual functionality ofMTDH further provides an explanation for the long-standing conceptual dilemma
regarding the selection ofmetastasis genes in the primary tumor. Overall, our data illustrate the synergistic value of integrat-
ing bioinformatics with clinical and experimental metastasis research.Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc. 9
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MTDH Promotes Chemoresistance and MetastasisFigure 1. ACE Analysis Identifies a Recurrent Genomic Gain at 8q22 in Poor-Prognosis Breast Cancer
(A) In the ACE (analysis of CNAs by expression data) approach, the expression score (ES) of each gene is calculated by comparing samples of different pheno-
types, and then a neighborhood score (NS), indicative of the DNA copy number status, is computed for each locus as the geometry-weighted ES sum of all of the
genes on the chromosome. Regions of gain (red, bottom panel) and loss (green) were defined by applying NS cutoffs (dotted lines) obtained from permutations.
i and j, gene index when genes are ordered on the chromosome by genomic positions; c, normalizing constant;wji, weight of gene jwhen locus i is in consideration
(see text and Experimental Procedures for details).
(B) Poor-prognosis genomic gain at 8q22 was detected in all three data sets analyzed (van’t Veer et al., 2002; van de Vijver et al., 2002; Wang et al., 2005). The
traces are the NS scores on chromosome 8 produced by ACE. The shaded area highlights the consensus region of gain at 8q22. Red and green peaks represent
statistically significant regions of gains and loss, respectively.
(C) Kaplan-Meier metastasis-free survival curves of patients with high or low 8q22 NS.human cancers (Ramaswamy et al., 2003; van’t Veer et al., 2002;
van de Vijver et al., 2002; Wang et al., 2005). Although different
poor-prognosis signatures have proven to be operationally inter-
changeable for class prediction purposes in the clinic (Fan et al.,
2006), the lack of overlap between different poor-prognosis
signatures has posed a major challenge for understanding the
biological underpinnings of cancer progression and metastasis,
thereby hindering the development of targeted therapeutics.
Identifying functionally important and clinically relevant metasta-
sis genes requires innovative strategies to synergize advances in
both clinical and experimental metastasis studies.
Recurrent DNA copy number alterations (CNAs) have been
observed in a wide range of human cancers, and such genetic
events often indicate the presence of key mediators of malig-
nancy in the affected genomic loci. For example, elevated
expression of oncogenes, such as c-Myc, CCND1, Her2, and
EGFR1, is often a result of amplification of their corresponding
genomic segments (Chin and Gray, 2008). However, CNAs
responsible for cancer metastasis are poorly characterized.
Various techniques have been developed to detect genomic
alterations, including fluorescence in situ hybridization (FISH),
comparative genomic hybridization (CGH), and high-density sin-
gle-nucleotide polymorphism (SNP) genotyping. Detection of
CNAs by expression profiling analysis is theoretically possible
since a strong correlation between genomic alterations and10 Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc.aberrant expression of genes in affected loci has been observed
(Pollack et al., 2002). Accurate detection of CNAs using expres-
sion analysis, however, is technically difficult because gene
expression data reflect multiple layers of gene regulation beyond
genomic alterations. Such analysis is particularly challenging
with clinical tumor samples due to the inherent heterogeneity of
clinical specimens and the rampant genomic instability of late-
stage tumors. Here we used a computational algorithm to identify
a recurrent genomic gain in poor-prognosis human breast can-
cers in 8q22, which harbors the metastasis gene metadherin
(MTDH; also called Lyric and AEG1 [Britt et al., 2004; Brown
and Ruoslahti, 2004; Kang et al., 2005]). Functional characteriza-
tion of MTDH revealed its dual functions in promoting metastasis
and chemoresistance of breast cancers.
RESULTS
Recurrent Poor-Prognosis Genomic Alterations
To sensitively detect CNAs that affect regional gene expression,
we developed a bioinformatic strategy called ACE (analysis of
CNAs by expression data; Figure 1A). ACE first calculates the
expression scores of all genes according to their expression dif-
ferences between comparison groups and then orders them by
genomic positions. To measure the regional expression pattern,
a neighborhood score (NS) is calculated for each genomic locus
Cancer Cell
MTDH Promotes Chemoresistance and MetastasisTable 1. Recurrent Regions of Gain Associated with Poor-Prognosis Breast Cancer as Detected by ACE
# Location Genomic Position (Mb) Size (Mb) Gene Number Predicted in Data Sets
1 8q22 96.3–99.2 2.9 20 all
2 3q26.33-q27.1 180.2–184.4 4.2 27 Wang et al.; van’t Veer et al.
3 8q24.3 144.4–145.7 1.3 82 Wang et al.; van de Vijver et al.
4 17q23.3-q25 54.8–58.2 3.4 42 Wang et al.; van de Vijver et al.
5 20q13.3 60.7–62.0 1.3 60 Wang et al.; van de Vijver et al.using a geometry-weighted sum of expression scores of all the
genes on the chromosome. The expression scores of the genes
in proximity to the locus in consideration are assigned greater
weights than those farther away because the locus linkage
strength decays with distance. The significance of the NS is es-
timated by permutation, and regions with a stretch (R20) of ab-
errant NS are declared as potential CNA regions.
After validating the efficacy of the ACE method using a number
of existing gene expression profiling data sets that have corre-
sponding genomic alteration information (see Figure S1 and Sup-
plemental Experimental Procedures available online), we applied
it to the study of genomic alterations associated with poor prog-
nosis of human breast cancer. Three separate studies have
previously identified two poor-prognosis gene sets of 70 and 76
genes that can be used to robustly predict the clinical outcome
of human breast cancers (van’t Veer et al., 2002; van de Vijver
et al., 2002; Wang et al., 2005). However, only a single gene
(CCNE2) is present in both signatures. When the ACE method
was applied to analyze these three data sets, five common geno-
mic gains were observed in at least two data sets (Table 1), and 15
other genomic gains were observed in one of the three data sets
(Table S1). The smallest regions of overlap (SROs) of common
CNA events—namely, gains at 3q26-27, 8q22, 8q24.3, 17q23-
25, and 20q13.3—are among a large number of genomic alter-
ations previously observed in high frequencies in breast cancer,
although their links to poor prognosis and tumor progression
have not been established (Bergamaschi et al., 2006). We did
not detect any genomic losses associated with more than one
data set, which is consistent with previous observations that
genomic gains are more prevalent than genomic losses in breast
cancer, especially in patients with poor outcomes (Naylor et al.,
2005). Out of the five prevalent genomic events, the 8q22 gain
was consistently observed in all three data sets (Figure 1B). We
calculated the NS of this region for each sample in the three
data sets and used it to classify tumor samples into two groups
with high and low NS. As shown in Figure 1C and Table S2, the
probability of metastasis-free survival of patients with a high
8q22 NS was significantly lower than that of the control group in
all three data sets. These analyses suggested that genomic gain
of 8q22 is a strong predictor of poor prognosis in breast cancer.
During tumor progression, cancer cells usually acquire multi-
ple genomic alterations. These genetic events may contribute
to tumor aggressiveness independently or synergistically. To
examine whether the other four regions interact with 8q22 gain
in poor prognosis, we clustered the tumor samples in the three
data sets according to the NS of the five regions (Figure S2). A
significant fraction of samples with 8q22 gain also showed in-
creased copy numbers at 8q24.3 (p < 0.01, c2 test) in all three
data sets, but no obvious link was found between 8q22 andthe other three regions. The concurrent copy number gains of
the two 8q subregions is consistent with the previous observa-
tion of frequent genomic gain of the whole 8q arm in breast
cancer tumors (Ried et al., 1995). However, survival analysis re-
vealed no significant contribution of 8q24.3 to the prognostic
power of 8q22, as patients with genomic gains at both regions
displayed survival records similar to, or even better than, pa-
tients with 8q22 gain only (Figure S2), suggesting that 8q22
gain functions independently in poor prognosis.
Validation of 8q22 Genomic Gain in Breast Tumors
We used FISH and genomic DNA quantitative PCR (qPCR) to con-
firm 8q22 genomic gain in breast tumor samples. First, we
analyzed a panel of microdissected tumor samples from fresh-
frozen breast cancer specimens by qPCR using four pairs of
primers that amplify DNA sequences at chromosome 8q21,
q22, and q23 (Figures 2A and 2B). Out of 36 tumors, 10 (27.8%)
were found to have aberrantly higher copy numbers (>3.6) at
8q22 than the control human DNA sample (Table S3). As shown
in Figure 2B, the ten genomic gain events spanned from 8q21 to
8q23 with a consensus region at 8q22, consistent with our com-
putational prediction. DNA copy numbers detected by genomic
qPCR analysis were consistent with FISH analysis of the same
tumor specimens (Figure S3). To confirm the link between 8q22
genomic gain and elevated expression of genes located in this re-
gion, we used qRT-PCR to investigate the expression patterns of
three genes at 8q22 (PTDSS1, MTDH, and LAPTM4b) in these
tumors. A strong positive correlation was found between the ex-
pression of these genes and the 8q22 copy numbers (Figure 2B).
Similar results were obtained when we analyzed a separate panel
of 18 paraffin-embedded breast tumors (Table S3). Analysis of
a panel of breast cancer cell lines also found a good correlation
of 8q22 gain with a higher level of MTDH expression (Figure S3).
We further analyzed a breast cancer tissue microarray with
detailed clinicopathological records by FISH using a bacterial ar-
tificial chromosome (BAC) probe located at the 8q22 region and
found that 22 (26.8%) of the 82 hybridized primary tumor samples
had an average 8q22 copy number larger than 3 (Figure 2C; Table
S4). Notably, 8q22 gain was associated with a higher propensity
of metastatic recurrence (Figure 2D). Together with the qPCR
analysis described above, these data confirmed the ACE predic-
tion that recurrent genomic gain at 8q22 leads to regional gene
activation. More importantly, these results established 8q22
gain as a poor-prognosis marker event in breast cancer.
MTDH Promotes Breast Cancer Metastasis
There are 13 known genes and 7 hypothetical genes in the 8q22
poor-prognosis genomic gain region (Figure 2A). Overexpres-
sion of several genes in this region was independently linked toCancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc. 11
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MTDH Promotes Chemoresistance and Metastasispoor prognosis in one or more data sets (Table S5). To determine
the functional targets of 8q22 gain, we tested six known genes
most likely to promote cancer progression based on statistical
analysis and their known biological functions: UQCRB, PTDSS1,
TSPYL5,MTDH, and LAPTM4b, which were significantly overex-
pressed in metastatic diseases in at least two of these data sets
(Student’s t test, p < 0.05), andSDC2, which has been reported to
mediate cell adhesion and proliferation in colon cancer (Park
et al., 2002) (Figure S4). To test the role of these genes in metas-
tasis, we stably overexpressed them in the SCP28 cell line, a
subline of the human breast cancer cell line MDA-MB-231 that
is mildly metastatic to lung and bone when injected into mice
(Kang et al., 2003). The cell line was labeled with a retroviral con-
struct expressing a GFP-luciferase fusion protein (Minn et al.,
2005), and its in vivo metastasis capability was monitored by
noninvasive bioluminescent imaging (BLI) after intravenous injec-
tion. Our data showed that MTDH overexpression significantly
accelerated the development of lung metastasis and shortened
the survival of mice that received tumor cell xenografts (Figures
3A–3D; Figure S4). Animal metastasis burden caused by MTDH
overexpression was nearly 7-fold higher than the controls 6
weeks after cancer cell injection. In contrast, overexpression of
the other five genes, either individually or in combination, failed
to enhance the metastasis ability of SCP28 (Figure S4). Further-
more, overexpression of these genes together withMTDHdid not
further enhance lung metastasis beyond MTDH overexpression
alone (Figure S4). Therefore,MTDH is likely to be the most signif-
icant functional mediator of this poor-prognosis genomic gain,
although possible contributions from untested genes in the
8q22 region cannot be completely ruled out. MTDH is located
MTDH
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Figure 2. Validation of 8q22 Genomic Gain
in Human Breast Tumors
(A) Expression of the genes at the 8q22 region in
poor-prognosis versus good-prognosis samples
of the three data sets. Red indicates overexpres-
sion; green indicates underexpression.
(B) To validate the 8q22 genomic gain, a panel of
breast tumors were analyzed for 8q22 genomic al-
terations and gene expression using qPCR. DNA
copy numbers of four genomic loci at 8q21-23
(circles) and expression levels of three genes at
8q22 (diamonds) are shown. Student’s t test p
values of expression comparison in samples
with and without 8q22 gain are shown in parenthe-
sis after each gene.
(C) Breast cancer tissue microarray fluorescence
in situ hybridization (FISH) analysis with green
SpectrumGreen and orange SpectrumOrange
probes detecting the chromosome 8 centromere
and the 8q22 region, respectively. A case of
8q22 gain (left) and a diploid case (right) are
shown.
(D) Kaplan-Meier survival analysis in breast
cancer patients with or without 8q22 gain.
at the center of the minimal common
region of the 8q22 genomic gain as indi-
cated by the ACE computational analy-
ses of three microarray data sets and
has been shown to encode a cell surface
protein responsible for promoting mouse mammary tumor cell
adhesion to lung endothelial cells (Brown and Ruoslahti, 2004).
However, the functional role of MTDH in human breast cancer
and the mechanism of its deregulation have not been previously
investigated.
To further validate the role of MTDH in metastasis, we used two
different short-hairpin RNA (shRNA) constructs to knock down
the expression of MTDH in the LM2 cell line, an MDA-MB-231
subline selected in vivo for its high lung metastasis propensity
(Minn et al., 2005). The in vivo metastatic propensity of LM2 cells
withMTDHknockdown was tested in nude mice after intravenous
injection. MTDH knockdown significantly reduced the lung
metastasis burden of LM2 by 3- to 5-fold and extended survival
of the mice by 1–2 weeks (Figures 3A and 3E–3G; Figure S4).
Histological analysis of primary tumors and lung metastases re-
vealed poorly differentiated adenocarcinomas at both sites with
very similar histological features (Figure S5). We further quantified
the mRNA level ofMTDH in cancer cells isolated from lung metas-
tases (Figure S5). Cells isolated from lung lesions produced by
MTDH knockdown cells continued to have a low level of MTDH
expression, but modestly higher than the MTDH level in cells
grown in culture, suggesting that the in vivo lung metastasis
assay may select for ‘‘escapers’’ that have regained a higher level
of MTDH expression.
We also examined the effect of altered MTDH expression on
bone and brain metastasis by injecting the genetically modified
breast cancer cell lines into the left cardiac ventricle of recipient
nude mice. MTDH knockdown in LM2 resulted in a modest but
significant improvement of postinjection survival, although biolu-
minescence quantification of the decrease of bone and brain
12 Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc.
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Figure 3. MTDH Mediates Lung Metastasis of Human Breast Cancer
(A) Metadherin (MTDH) is constitutively overexpressed in the mildly metastatic cell line SCP28 and stably knocked down in the highly lung-metastatic cell line LM2
with two independent short-hairpin constructs.
(B) In vivo metastasis assays of SCP28 cells with or without MTDH overexpression. Lung metastasis burden of xenografted animals was monitored weekly using
bioluminescent imaging (BLI). Shown are BLI images of representative mice at the sixth week after injection. The color scale depicts the photon flux (photons per
second) emitted from the metastasis cells.
(C) BLI quantification of lung metastasis of SCP28 cells.
(D) Kaplan-Meier survival curves of mice injected with SCP28 cells.
(E) Representative BLI images (left) and lung sections (right) of inoculated mice at the sixth week after injection of LM2 cells with or without MTDH knockdown.
Arrows point to sporadic lesions by MTDH knockdown cells as compared to much more prevalent tumor lesions by control cells. Scale bars = 0.5 mm.
(F) BLI quantification of lung metastasis of LM2 cells. Data in (C) and (F) represent averages ± SEM of 10 mice. *p < 0.05; **p < 0.01 by two-sided Wilcoxon
rank test.
(G) Kaplan-Meier survival analysis of mice injected with LM2 cells.
(H) Genetically modified SCP28 or LM2 cells were seeded on top of a monolayer of endothelial cells from lung (HMVEC-L), umbilical vein (HUVEC), bone marrow
(HBMEC60), and control fibroblast (WI38) cells, and the attached cells were quantified 3 hr later. Data represent averages ± SEM.metastasis burden did not reach statistical significance. Con-
versely, overexpression of MTDH in SCP28 cells led to a modest
but significant increase of bone and brain metastasis (Figure S6).
These results suggested that MTDH preferentially promotes
metastasis to lung while having a modest effect on metastasis
to other organs.
We further investigated the functional role of MTDH in the
multistep process of metastasis. MTDH knockdown or overex-
pression did not affect the growth, migration, or invasiveness
of various breast cancer cell lines, including MDA-MB-231 sub-
lines (Figure S7), MCF7, and T47D (Figure S8 and data not
shown). However, MTDH knockdown significantly reduced the
adhesion of cancer cells to lung microvascular endothelial cells(HMVEC-L), as well as to endothelial cells of the bone marrow
(HBMEC60) and the umbilical vein (HUVEC), albeit to a lesser
extent. A reciprocal change was observed when MTDH was
overexpressed (Figure 3H). In contrast, the adhesion of cancer
cells to the WI38 lung fibroblast cell line was not affected.
MTDH-mediated enhancement of tumor cell adhesion to endo-
thelial cells was also observed in other breast cancer cell lines,
including MCF7 and T47D (Figure S8). MTDH did not promote
intravasation or extravasation through endothelial layers based
on both in vitro transendothelial assays and in vivo metastasis
assays using an orthotopic xenograft method (data not shown).
Instead, MTDH appeared to specifically enhance the seeding
of tumor cells to the target organ endothelium.Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc. 13
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Figure 4. MTDH Enhances Chemoresistance of Breast Cancer Cells
(A) Genomic gain of 8q22 is associated with higher resistance to chemical compounds in the 58 human cancer cell lines. LogGI50 (drug concentration for 50%
growth inhibition) of each of the 24,642 compounds in cell lines with 8q22 gain was compared to those in cells without 8q22 gain. The numbers of compounds with
significantly increased logGI50 associated with 8q22 gain, counted by applying various significance thresholds of the logGI50 differences (p < 0.05, 0.01, and
0.001), were compared to a null distribution obtained by permuting the 8q22 copy numbers of the cell lines. Median values from permutations are shown,
with mean absolute deviation (MAD) as the error bar.
(B) Chemoresistance of LM2 cells was analyzed by clonogenic assays after treatment with various apoptosis-inducing agents with or without HMVEC-L cocul-
ture. Relative clonogenic abilities as percentages of the nontreatment control are shown.
(C) Representative images of clonogenic assays of LM2 cells.
(D) Clonogenic assays of SCP28 cells with overexpression of MTDH or other genes in the 8q22 region. Data with HMVEC-L coculture are shown.
(E) In vivo chemoresistance assay of LM2 cells. Xenograft tumor volumes in mice treated with paclitaxel or drug vehicle are shown (n = 6 mice per group). Results
in (B), (D), and (E) represent average values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by two-sided Student’s t test.
(F) Representative tumors isolated from mice 25 days after injection in the in vivo chemoresistance assay.MTDH Promotes Chemoresistance
Poor prognosis of breast cancer at the time of diagnosis or
surgery indicates a higher probability of death as the result of
recurrent tumors and development of metastases in vital organs.
Emergence of metastasis reflects not only the ability of cancer
cells to overcome hurdles during the multistep process of metas-
tasis but also the capability to survive standard adjuvant therapy
and other physiological stresses. Therefore, the driver gene of a
poor-prognosis genetic alteration might function to promote
chemoresistance in addition to enabling the metastasis process.
A bioinformatic analysis of the available NCI60 pharmacoge-
nomic data (Garraway et al., 2005) indicated a potential contribu-
tion of the genes at 8q22 to chemoresistance. The NCI60 data
include the cytogenetic and expression profiles of 58 cancer cell
lines as well as their sensitivity profiles to 24,000 small-molecule
compounds. Analysis of these data revealed that genomic gain
at 8q22 strongly correlated with a higher overall gene expression14 Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc.of this region (Pearson’s r = 0.578; Figure S9); intriguingly, this
higher NS was in turn associated with a significantly higher mean
GI50 (the drug concentration for 50% growth inhibition) for 1,123
compounds, as compared to 211 ± 178 compounds expected
by random permutation (p = 0.019; Figure 4A). In contrast, copy
number of the other 8q poor-prognosis region, 8q24.3, was
not associated with any significant changes in GI50 values
(Figure S10). Similar analysis with the mRNA expression data
of the genes at 8q22 revealed that MTDH is the only gene
that has a significant correlation with higher chemoresistance
(Table S6).
To investigate the chemoresistance function of MTDH and the
other genes in 8q22, genetically modified LM2 breast cancer cell
lines used for in vivo metastasis assays were treated with chemo-
therapeutic or other stress agents including paclitaxel, doxorubi-
cin, cisplatin, and hydrogen peroxide with or without coculture
with the HMVEC-L endothelial cell line. Long-term survival of
Cancer Cell
MTDH Promotes Chemoresistance and Metastasisthe cells was then quantified by clonogenic assays. Inhibition of
MTDHexpression sensitized the LM2 cell line to chemotherapeu-
tic and stress agents, while overexpression of MTDH rendered
SCP28 cells more resistant to these treatments (Figures 4B–
4D). In contrast, overexpression of up to four other genes in the
8q22 locus did not significantly alter the chemosensitivity of
cancer cells (Figure 4D). MTDH-dependent chemoresistance
was further enhanced when cancer cells were cocultured with
HMVEC-L endothelial cells (Figures 4B and 4C). MTDH-induced
chemoresistance was not limited to the MDA-MB-231 cells, as
MTDH knockdown in several additional breast cancer cell lines,
including MCF7 and T47D, also significantly sensitized cells to
chemotherapeutic challenges (Figure S8).
Next, we studied the chemoresistance function of MTDH
in vivo using xenograft models. LM2 cells with or without MTDH
knockdown were injected into nude mice subcutaneously.
Twice-weekly treatment of tumors with paclitaxel or drug vehicle
was initiated at 1 week after injection. Subcutaneous tumor
volumes were monitored by direct caliper measurement. When
the mice were treated with drug vehicle, the LM2 tumors grew
rapidly, reaching five times the initial volume at 18 days after
treatment (Figure 4E). Tumors from the MTDH knockdown cells
grew at an equal rate, an observation consistent with the finding
that MTDH does not affect primary tumor growth (Figure S7).
Paclitaxel treatment significantly hampered tumor growth in
mice injected with control LM2 cells. However, the tumors still
grew to 140% in volume 18 days after treatment, indicating a
considerable degree of chemoresistance in these cancer cells.
MTDH knockdown significantly sensitized the cells to paclitaxel
treatment, as tumor regression was observed immediately after
the first treatment. The tumors eventually shrank to about 30%
of pretreatment size 18 days after the initiation of treatment
(Figures 4E and 4F). Similar results were obtained with another
commonly used chemotherapeutic agent, doxorubicin (Fig-
ure S11).
ALDH3A1 and MET Contribute to MTDH-Induced
Chemoresistance
We performed drug uptake and retention assays for paclitaxel
and doxorubicin in cancer cells with modified MTDH expression
and found that MTDH did not change drug uptake or retention in
these cells (Figure S12). Without a direct function in altering drug
accumulation, MTDH may instead increase chemoresistance by
promoting cellular survival against antineoplastic stresses. To
further elucidate the molecular mechanism of MTDH-dependent
chemoresistance, we compared gene expression profiles of two
differentMTDH knockdown LM2 cell lines against control cells. A
similar comparison was also performed with LM2 cells cocul-
tured with HMVEC-L cells (Figure 5A; Table S7). In the latter
analysis, LM2 and HMVEC-L cells were labeled with GFP and
seminaphthorhodafluor-1 (SNARF-1) dye, respectively, to allow
fluorescence-activated cell sorting (FACS) of the two cell popula-
tions before RNA extraction (Figure 5B). Since MTDH induces
significant chemoresistance with or without HMVEC-L coculture,
we focused our attention on the significant genes (>2.5-fold
change in expression; Student’s t test p < 0.05) that were consis-
tently present in both conditions. Twenty-three genes (including
MTDH) were found to be underexpressed in MTDH knockdown
cells, while ten genes were overexpressed. Among the MTDH-downregulated genes (i.e., genes upregulated following MTDH
knockdown) were two cell death-inducing genes, TRAIL and
BINP3. TRAIL encodes a TNF-family cytokine that induces
apoptosis in tumor cells. Combining TRAIL with conventional
anticancer drugs has been shown to improve therapeutic efficacy
of chemotherapies (Ballestrero et al., 2004). BNIP3 is a proapop-
totic Bcl-2-family gene that has been shown to be involved
in apoptotic, necrotic, and autophagic cell death (Mellor and
Harris, 2007). Among the MTDH-upregulated genes were several
genes previously implicated in chemoresistance of cancer cells,
including ALDH3A1, MET, HSP90AB1 (Bertram et al., 1996),
HSP90AB3P, and HMOX1 (Tanaka et al., 2003). The expression
pattern of these genes inMTDH knockdown cells was confirmed
by qPCR analysis using samples from both cell cultures and LM2
xenograft tumors (Figure 5C). The regulation of these genes by
MTDH was additionally validated in three other breast cancer
cell lines (MCF7, T47D, and BT474) usingMTDH knockdown (Fig-
ure S8). Furthermore, a significant correlation of the expression of
MTDH and its downstream genes was found in the NCI60 panel
of human cancer cell lines as well as in primary breast tumor
samples by computational analysis (Figure S13).
Among these candidate MTDH downstream genes, ALDH3A1
(aldehyde dehydrogenase 3 family, member A1) andMET (hepa-
tocyte growth factor receptor) are attractive targets because of
their physiological functions and their expression patterns. Anti-
neoplastic agents have been shown to produce oxidative stress
in tumors during cancer chemotherapy. These effects are medi-
ated in part by the generation of aldehydes that result from oxida-
tive stress-induced lipid peroxidation. ALDH3A1 encodes an
antioxidant enzyme with several postulated protective roles
that include detoxification of peroxidic aldehydes and scaveng-
ing of free radicals. Its expression has been implicated in clinical
resistance to cyclophosphamide (Sreerama and Sladek, 2001),
which is a mainstay of chemotherapeutic regimens used to treat
breast cancers. Aldehyde dehydrogenase activity has also been
shown to be a marker of cancer stem cells and may contribute to
their increased chemoresistance (Croker et al., 2008; Ginestier
et al., 2007). Interestingly, as revealed by microarray analysis
(Figure 5A) and further confirmed by qRT-PCR (data not shown),
ALDH3A1 expression was 2- to 3-fold higher in the HMVEC-L co-
culture as compared to the non-coculture condition, whileMTDH
knockdown effectively repressed ALDH3A1 expression in both
conditions. Such an expression pattern matches the higher che-
moresistance of cancer cells induced by HMVEC-L coculture and
chemosensitization by MTDH knockdown in both conditions. To
investigate the functional importance of ALDH3A1 in MTDH-me-
diated chemoresistance, we engineered the LM2 cell line to ex-
press an inducible shRNA against ALDH3A1 in order to produce
conditional knockdown ofALDH3A1. LM2 cells were more sensi-
tive to the chemotherapeutic agents paclitaxel, doxorubicin, and
4-hydroxycyclophosphamide (4-HC) when ALDH3A1 knock-
down was induced by addition of doxycycline, while release of
ALDH3A1 repression restored the chemoresistance of LM2 cells
(Figure 5D).
We also tested the chemoresistance function of MET. In hu-
man patients, enhanced expression or activation of MET is ob-
served in nearly all tumor types. In most cases, its expression
is associated with both resistance to radio- and chemotherapy
and poor prognosis (Birchmeier et al., 2003). In experimentalCancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc. 15
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Figure 5. ALDH3A1 and MET Contribute to MTDH-Mediated Chemoresistance
(A) Expression pattern of genes regulated in MTDH knockdown cells with or without HMVEC-L coculture. Names of some genes previously implicated in pro-
moting (red) or suppressing (green) cellular chemoresistance are highlighted.
(B) In the coculture microarray experiment, HMVEC-L cells were prelabeled with seminaphthorhodafluor-1 (SNARF-1) dye and separated from GFP+ LM2 cells by
fluorescence-activated cell sorting (FACS) before microarray profiling.
(C) qPCR analysis of the expression patterns of genes downregulated (red) or upregulated (green) in MTDH knockdown cells identified by microarray analysis.
(D) ALDH3A1 expression levels (top) and clonogenic assays (bottom) of cells engineered with ALDH3A1-inducible knockdown.
(E) Gene expression (top) and clonogenic assays (bottom) of cells with MET knockdown or MET + ALDH3A1 double knockdown.
(F) Gene expression (top) and clonogenic assays (bottom) of ALDH3A1 or MET overexpression rescue in LM2 cells with MTDH knockdown. In (D)–(F), data rep-
resent average ± SEM of three replicates. *p < 0.05, **p < 0.01 by two-sided Student’s t test.models, exogenous hepatocyte growth factor (HGF) or overex-
pression of MET induces resistance to ionizing radiation and
many chemotherapeutics, including doxorubicin, cisplatin, eto-
poside, camptothecin, paclitaxel, TNF, and gefitinib, in diverse
human cancer cells from different tumor types, as well as in en-
dothelial cells (Engelman et al., 2007; Wei and Au, 2005). MET
knockdown in LM2 cells led to a significant reduction of chemo-
resistance to doxorubicin, an effect similar to but weaker than
that of MTDH knockdown (Figure 5E). When MET and ALDH3A1
were simultaneously knocked down in LM2 cells, the chemosen-
sitizing effects reached a level comparable to that of MTDH
knockdown (Figure 5E). We further tested the ability of ALDH3A1
and MET to rescue the chemoresistance phenotype in MTDH
knockdown cells. Constitutive overexpression of ALDH3A1 or
MET in the MTDH knockdown cells was able to partially rescue
the chemoresistance of LM2 cells to paclitaxel, doxorubicin,
and 4-HC (Figure 5F). Together, these results suggest that
ALDH3A1 and MET are among the MTDH downstream genes
that collectively contribute to its role in broad-spectrum chemo-
resistance.16 Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc.MTDH Correlates with Poor Prognosis
in Clinical Samples
To evaluate the clinical importance of MTDH in breast cancer, we
stained the tissue microarray used in the previous FISH analysis
using an antibody against MTDH. Among the 170 samples on the
tissue microarray, 47% expressed MTDH at a moderate to high
level (Figure 6A). Overexpression of MTDH was not linked to any
specific breast tumor subtype in terms of HER2 status, triple
marker status (ER/PR/HER2), or the basal epithelial cell marker
CK5/6 status (Figure S14) but was significantly associated with
a higher risk of metastasis (log rank, p = 0.0058) and shorter sur-
vival time (p = 0.0008). Univariate survival analysis using the Cox
proportional hazards model also suggested that high MTDH ex-
pression is strongly associated with a higher hazard ratio (HR)
and worse clinical outcomes (HR = 3.7, p = 0.01 for metastasis;
HR = 8.3, p = 0.005 for cancer-related death). Of note, immuno-
histochemical analysis of CCNE2 protein expression (encoded
by the only gene present in both poor-prognosis signatures iden-
tified by van’t Veer et al. [2002] and Wang et al. [2005]) in the
same breast tumor tissue array did not reveal any significant
Cancer Cell
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Prognosis of Human Breast Tumors
(A) Typical MTDH immunostaining images of a
human breast cancer tissue microarray.
(B) MTDH protein levels are positively correlated
with FISH 8q22 DNA copy numbers.
(C) High MTDH protein level is associated with
early metastasis in cancer patients.
(D) High MTDH expression is also associated with
worse cancer-specific survival.
(E) A schematic model for the dual role of MTDH in
breast cancer progression. In poor-prognosis tu-
mors, 8q22 genomic gain leads to overexpression
of MTDH, which in turn activates two parallel pro-
grams to promote chemoresistance and metasta-
sis. Elevated expression of the chemoresistance
genes ALDH3A1, MET, HMOX1, and HSP90, as
well as repression of the apoptosis-inducing
genes TRAIL and BNIP3, promotes the survival
and outgrowth of cancer cells in the primary site
as well as secondary organs in the face of physio-
logical stress and chemotherapeutic challenges.
MTDH additionally promotes metastasis by medi-
ating tumor cell adhesion through interactions with
unknown receptors and by activating prometasta-
sis genes and suppressing metastasis-suppress-
ing genes. Some of the molecular mediators of
MTDH function may play a role in both functional
categories. For example, MET can promote both
metastasis and chemoresistance, and endothelial
adhesion can further enhance MTDH-mediated
chemoresistance.correlation with metastasis (Figure S15). Interestingly, CCNE2 is
located in very close proximity to the recurrent 8q22 genomic
gain (Figure S15; Table S5). It is possible that the recurrent pres-
ence of CCNE2 in multiple poor-prognosis signatures is due to
its close physical linkage to 8q22.
We further analyzed the correlation of MTDH protein levels
with 8q22 DNA copy numbers using the samples with both suc-
cessful immunostaining and FISH results. While the data showed
that all but one of the tumors with 8q22 gain expressed abundant
(medium or high) levels of MTDH protein (Figure 6B; c2 test
p < 0.001), a substantial fraction (12%) of samples with normal
DNA copy numbers also had high levels of MTDH protein. There-
fore, alternative mechanisms distinct from 8q22 gain may also
result in MTDH activation in breast tumors. Nevertheless, sur-
vival analysis of the tumor samples in our tissue microarray
and in the three previously published data sets consistently
showed that MTDH activated by genomic gain or other means
leads to similar clinical outcomes (Figure S16).
To further analyze the prognostic significance of MTDH, we
performed Cox hazard ratio analysis of MTDH expression with
the tissue samples stratified by other common clinicopathologi-
cal parameters including ER, PR, HER2, and p53 status as well
as the sizes of primary tumors at the time of cancer diagnosis
(Table 2). MTDH expression level retained its prognostic signifi-
cance in these analyses, suggesting that it is a prognostic factor
independent of other clinicopathological factors. Indeed, a multi-
variate Cox analysis combining all of the above parameters with
MTDH expression showed that the hazard of metastasis was still
significantly higher with MTDH expression (p = 0.023) even when
all of the other factors were considered.DISCUSSION
In this study, we used the ACE algorithm to unveil functionally
significant cytogenetic events directly linked to altered gene ex-
pression in poor-prognosis tumors. High-throughput genomic
profiling methods such as array CGH (aCGH) and SNP arrays
have facilitated the recent discovery of several cancer genes
(Garraway et al., 2005; Kim et al., 2006). As an addition to the rep-
ertoire of integrative genomic analysis tools, ACE is particularly
useful when cytogenetic data are not available, or it can be
used as a complementary strategy to fine map results obtained
from cytogenetic analyses and help narrow the list of genes for
functional analysis. A further advantage of ACE is that it can
detect regional epigenetic alterations that cannot be discerned
by the aCGH or SNP array approaches (Figure S1). Additionally,
ACE provides a direct link between cytogenetic events and
gene activity changes, thereby facilitating the search for function-
ally important candidate genes. Given the large amount of
archived gene expression data available in the public domain
and the difficulty in obtaining matched cancer samples, ACE
will be a useful data mining tool to complement the direct copy
number detection methods to help shed light on the functional
mechanism of cancer progression.
Our ACE analysis of breast cancer, together with clinical and
functional studies of MTDH,strongly suggests thatMTDH is a me-
tastasis gene with great prognostic potential and therapeutic
value. Brown et al. previously used phage display to identify
MTDH as a homing receptor that mediates the adhesion of the
4T1 murine mammary tumor cell line to lung endothelial cells
and promotes lung metastasis (Brown and Ruoslahti, 2004). InCancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc. 17
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MTDH Promotes Chemoresistance and MetastasisTable 2. Cox Hazard Ratios for Metastasis in Breast Cancer Based on MTDH Expression Levels in Tissue Array Analysis
Pathological Parameter
MTDH Hazard Ratio in Stratified Analysisa Multivariate Analysisb
Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
MTDH 3.70 (1.36–10.0) 0.010 4.28 (1.32–13.9) 0.015
ER 3.91 (1.30–11.8) 0.015 3.13 (0.59–16.5) 0.180
PR 3.84 (1.27–11.6) 0.016 0.682 (0.17–3.76) 0.800
HER2 3.20 (1.20–9.99) 0.026 4.79 (1.75–19.6) 0.030
p53 4.09 (1.34–12.5) 0.012 0.60 (0.19–1.94) 0.400
ER+PR+HER2 2.47 (1.25–9.56) 0.017 3.15 (0.51–19.3) 0.200
Tumor size 4.21 (1.28–12.5) 0.007 2.38 (0.87–6.52) 0.090
a Univariate analysis of MTDH expression alone (first data row) or stratified by the indicated second parameter (all other data rows).
b Multivariate analysis of all parameters, including MTDH, ER, PR, HER2, p53, and tumor size.that study, only the mouse 4T1 cell line and the biologically irrel-
evant HEK293T cell line were used to analyze the lung-targeting
function of MTDH. The involvement of MTDH in human cancer,
however, has not been previously reported. In this study, we
used an extensive collection of human breast tumor samples to
demonstrate that elevated MTDH protein level is an important
prognostic factor independent of other clinicopathological fac-
tors. Our results indicated that a substantial proportion of human
breast tumors exhibit MTDH genomic copy gains with a subse-
quent increase in MTDH expression, which is clearly associated
with poor survival and higher risk of progression. We further firmly
validated the functional importance of MTDH in systemic metas-
tasis using a well-established model for human breast cancer
metastasis. The importance of MTDH in cancer metastasis might
not be limited to promoting lung-specific spread of breast tumor
cells. Although MTDH was previously reported to enhance
murine mammary tumor cell adhesion to lung endothelial cells
(Brown and Ruoslahti, 2004), we showed that MTDH also en-
hances the adhesion of human breast cancer cells to other endo-
thelial cell types, consistent with its function to increase systemic
metastasis in vivo of a mildly metastatic cell line. However,MTDH
overexpression alone in nonmetastatic breast cancer cell lines,
including BT20, ZR-75-1, and ZR-75-30, was not sufficient to
allow these cells to gain metastatic ability in animal assays
(data not shown). This is consistent with recent studies showing
that simultaneous overexpression of multiple metastasis genes
is often required to achieve high metastatic capabilities (Gupta
et al., 2007; Kang et al., 2003; Minn et al., 2005). Nevertheless,
our in vitro, in vivo, and clinical studies firmly established MTDH
as an appealing target for therapeutic intervention of metastatic
diseases.
Current standard treatment for breast cancer uses the combi-
nation of surgery to remove localized disease and chemotherapy
to eliminate systemic spreading. However, relapsed breast can-
cers almost invariably acquire resistance to chemotherapy and
are often inoperable. Thus, over 90% of breast cancer-related
deaths are due not to cancer at the primary site but rather to the
spread of chemoresistant cancer cells from the breast to second-
ary vital organs such as lung, bone, liver, and brain. Metastasis
and chemoresistance remain two major challenges to curative
therapy. Our study uncovered a role for MTDH in chemoresist-
ance of cancer cells. Thus, MTDH may be among an important
class of genes that play dual roles in metastasis and chemoresist-
ance (Figure 6E). This may explain why some of the metastasis18 Cancer Cell 15, 9–20, January 6, 2009 ª2009 Elsevier Inc.genes are selected for in the primary tumor—presumably as
a consequence of their ability to endow cancer cells with en-
hanced tolerance to therapeutic and physiological stresses that
human tumors may endure—but do not confer an apparent
growth advantage in animal tumorigenesis assays (Bernards
and Weinberg, 2002). In addition to promoting chemoresistance
of primary tumors, MTDH may also increase the risk of metastatic
recurrence by enhancing the survival of metastatic lesions
against chemotherapy (Figure 6E), although this was not proven
directly in our current study due to difficulty in segregating the
two functions (metastasis and chemoresistance) of MTDH in
the in vivo metastasis assays. Ongoing studies in our laboratory
have also validated the dual functions of MTDH in metastasis
and chemoresistance in prostate cancer (G.H., Y.W., R.A.C.,
Q.Y., J. Siddiqui, K.J. Pienta, and Y.K., unpublished data), sug-
gesting a potential broader functional involvement of MTDH in
the progression of a variety of cancers.
Microarray profiling of MTDH knockdown cells revealed
several genes, including ALDH3A1 and MET, that collectively
contribute to the multidrug chemoresistance function of MTDH.
Several other genes identified by the microarray experiment
may also contribute to the prometastasis function of MTDH. For
example, genes that are downregulated by MTDH inhibition in-
clude several previously reported metastasis-promoting genes
such asMET,ADAMTS1, andCTGF (Kang et al., 2003; Lorenzato
et al., 2002). Conversely, several genes that have been reported
to suppress metastasis, including GPR56, TIMP3, and TRAIL
(Lin et al., 2002; Manka et al., 2005; Xu et al., 2006), were overex-
pressed in the MTDH knockdown line (Figure 5A; Table S7). The
mechanism of regulation of these downstream genes by MTDH
and the identification of the functional partners of MTDH will be
important matters to be addressed by future studies.
In conclusion, we have used a combination of computational
biology, in vivo and in vitro functional metastasis assays, and
extensive clinical correlation analyses to identify the 8q22
poor-prognosis genomic gain that harbors the dual-function me-
tastasis gene MTDH. Overexpression of MTDH occurs in up to
40% of breast cancer patients and promotes metastatic seeding
as well as chemoresistance of breast tumors. There are several
potential applications of this study in the clinical management
of human breast cancer. Genomic gain and overexpression of
MTDH can become a powerful prognosis marker independent
from other well-established markers for breast cancer. Molecu-
lar targeting ofMTDHmay not only prevent the seeding of breast
Cancer Cell
MTDH Promotes Chemoresistance and Metastasiscancer cells to the lung and other vital organs but also sensitize
cancer cells to chemotherapy, thereby stopping the deadly
spread of breast cancer.
EXPERIMENTAL PROCEDURES
Development of ACE Algorithm
ACE (analysis of CNAs by expression data) detects genetic alterations in three
steps: (1) calculating neighborhood scores (NS) for each chromosomal locus as
an indicator of copy number alteration (CNA) likelihood at that locus; (2) esti-
mating the significance of the NS; and (3) defining the regions of gain and loss.
The expression score (ES) for each gene is first calculated according to the
correlation of its expression with the phenotypes in comparison. In this manu-
script, paired t statistics (for ovarian cancer cell lines) or independent t statis-
tics (for other data sets) were used to score gene expression. In general, other
metrics can also be used. Consider the genes 1, 2, $$$, N on a chromosome
ordered by their physical positions. We define the NS at locus i as the weighted
sum of the ES of this chromosome:
NSi =
XN
j =1
wjiESj;
wherewji is the weight of gene j. Because the linkage strength between two loci
becomes weaker as the distance increases, the weight wji decreases when
locus j is farther away from the locus i. The contribution from each gene is
weighted by a Gaussian function:
Wji = ce
ðjiÞ2=2s2 ;
where c is a constant to normalize all NS into a range of [1, 1]. The variation
parameter 2s2 controls the weight decay rate and was arbitrarily set to 100 in
the analyses presented here. An analysis using varying 2s2 values from 20 to
200 showed similar results, with slight shifts at the boundaries of detected
regions. For each locus, only the genes in its physical proximity will have mea-
surable influence on its NS because of weight decay. Positive and negative NS
suggest genomic gain and loss, respectively. To evaluate the significance of
the NS, the gene positions (or sample class labels, if the sample size is large
enough) are permuted 1000 times, and each time the NS are recomputed.
The p values of observed NS are then computed using the distribution of
permuted NS and adjusted to false discovery rate (FDR) q values by the Ben-
jamini-Hochberg procedure. In all of the CNA analyses presented in this man-
uscript, we defined a region of genomic gain as one with at least 20 continuous
positive NS of FDR q < 0.01, or a region of genomic loss as one in which such
NS are all negative. In the epigenetic analysis, we used a cutoff of five contin-
uous NS, as epigenetic regulation usually has a smaller functioning range.
ACE has been implemented as a software tool to analyze expression data
obtained from various array platforms and is available in the Supplemental
Data online.
Tumorigenesis and Metastasis Assays in Nude Mice
All animal work was performed in accordance with the guidelines of the Insti-
tutional Animal Care and Use Committee of Princeton University under ap-
proved protocols. 23 105 cells were washed in PBS and injected intravenously
into female athymic Ncr-nu/nu mice to study lung metastasis activity as de-
scribed previously (Minn et al., 2005). For bone metastasis analysis, 1 3 105
cells were injected into the left ventricle of the heart as described previously
(Kang et al., 2003). Noninvasive bioluminescence imaging was performed to
quantify the metastasis burden in the target organs using an IVIS 200 Imaging
System (Caliper Life Sciences) as described previously (Minn et al., 2005).
To study primary tumorigenesis, cancer cells harvested from culture were re-
suspended in PBS at a concentration of 13 107 cells/ml. An incision was made
in the abdomen, and the skin was recessed to locate the #4 mammary fat pad,
into which 105 cells (10ml) were injected under a dissection microscope. Primary
tumor volume was monitored weekly as described previously (Minn et al., 2005).
Human Tumor Samples
Tumor specimens were obtained from the Cancer Institute of New Jersey with
informed consent from all subjects in accordance with the institutional reviewboards of Princeton University and the University of Medicine and Dentistry of
New Jersey. Details on the characterization of each tumor specimen can be
found in Supplemental Experimental Procedures.
Statistical Analysis
The Kaplan-Meier method was used to estimate survival curves for human
patients and animals. Log-rank test and Wilcoxon test were used to compare
the differences between curves. Two-sided Wilcoxon rank test was performed
to analyze the bioluminescence imaging results in the in vivo studies. A two-
sided independent Student’s t test without equal variance assumption was
performed to analyze the results of luciferase assays and clonogenic assays.
ACCESSION NUMBERS
Microarray data reported herein have been deposited at the NCBI Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with the accession
number GSE9187.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, nine tables, sixteen figures, and the ACE software
package and can be found with this article online at http://www.cancercell.
org/supplemental/S1535-6108(08)00379-6.
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